샘플 요청 목록

 카트 문의
시장보고서
상품코드
1551477

세계의 담관암 시장

Bile Duct Cancer
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 392 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

담관암 세계 시장 규모는 2030년까지 3억 8,260만 달러에 달할 것으로 전망

2023년 2억 5,820만 달러로 추정되는 담관암 세계 시장은 2023년부터 2030년까지 연평균 5.8% 성장하여 2030년에는 3억 8,260만 달러에 달할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 수술 요법은 CAGR 7.3%를 기록하여 분석 기간 종료 시점에 1억 5,410만 달러에 도달할 것으로 예상됩니다. 화학 요법 분야의 성장률은 분석 기간 동안 CAGR 5.9%로 추정됩니다.

미국 시장 7,030만 달러로 추정, 중국은 CAGR 9.6%로 성장 전망

미국의 담관암 시장은 2023년 7,030만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 8,250만 달러 규모에 도달할 것으로 예상되며, 2023-2030년의 분석 기간 동안 9.6%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 2.3%와 5.9%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 연평균 3.6%의 성장률을 보일 것으로 예상됩니다.

세계 담관암 시장 - 주요 동향 및 촉진요인 요약

담관암의 복잡하고 어려운 점은 무엇일까?

담관암으로도 알려진 담관암은 간에서 담낭과 소장으로 담즙을 운반하는 담관에 발생하는 드물지만 매우 공격적인 암입니다. 그런데 이 암이 특히 어려운 이유는 무엇일까? 담관암은 초기에는 무증상인 경우가 많아 진행되기 전까지는 발견하기 어렵습니다. 황달, 복통, 원인 불명의 체중 감소 등의 증상이 나타날 때쯤이면 이미 치료 옵션이 제한되어 있는 경우가 많습니다. 또한 담관은 해부학적으로 간 깊숙이 위치하여 중요한 장기에 둘러싸여 있어 진단과 수술적 개입이 복잡하며, MRI, CT 스캔, 담관 조영술과 같은 특수 기술과 같은 영상 검사는 종양의 위치를 파악하는 데 필수적이지만 담도계의 복잡한 구조로 인해 결론을 내리지 못하거나 해석이 어렵습니다, 해석이 어려울 수 있습니다. 이러한 복잡성은 담관암과의 싸움에서 보다 효과적인 진단 도구와 조기 발견 전략의 시급한 필요성을 강조하고 있습니다.

담관암의 치료 옵션이 제한적인 이유는 무엇일까?

암 치료의 발전에도 불구하고 담관암에 대한 치료법이 제한적인 이유는 무엇일까? 첫 번째 이유는 이 질병이 희귀한 질병이기 때문에 일반적인 암에 비해 광범위한 조사와 임상시험이 이루어지지 않았기 때문입니다. 국소 담관암의 표준 치료는 수술, 특히 담관이나 간 부위의 절제술입니다. 그러나 수술은 암이 조기에 발견되고 다른 장기로 전이되지 않은 경우에만 수술이 가능합니다. 안타깝게도 많은 환자들은 진단이 늦어 수술이 불가능하기 때문에 화학요법과 방사선 요법이 치료의 주축이 됩니다. 이러한 치료법은 질병의 진행을 늦추는 효과가 있을 수 있지만 완치에는 이르지 못하며 종종 심각한 부작용을 동반합니다. 최근 들어 건강한 조직을 보존하면서 암세포를 보다 정확하게 공격하는 표적치료제와 면역치료제가 개발되고 있으며, FGFR2 억제제, IDH1 억제제 등 담관암과 관련된 특정 유전자 돌연변이를 표적으로 하는 치료제는 임상시험에서 유망한 결과를 보이고 있어 향후 더욱 효과적인 치료가 가능할 것으로 기대됩니다. 효과적인 치료를 기대할 수 있습니다. 그러나 다양한 아형과 분자 프로파일을 가진 암의 불균일성은 만능 치료 접근법 개발을 복잡하게 만들고 있습니다.

담관암 연구의 최신 동향은?

담관암에 대한 조사가 강화되고 있는 가운데, 환자들의 전망을 바꿀 수 있는 최신 동향은 무엇일까? 중요한 트렌드 중 하나는 맞춤의료에 대한 관심이 높아지고 있다는 점입니다. 점점 더 많은 연구자들이 환자 개개인의 암 특성을 이해하는 데 있어 유전자 프로파일링의 중요성을 인식하고 있습니다. 특정 유전자 돌연변이 및 분자 표적을 파악하면 기존 화학요법보다 더 효과적인 맞춤 치료 계획을 세울 수 있습니다. 또 다른 트렌드는 면역요법(신체의 면역체계를 활용하여 암과 싸우는 방법)에 대한 탐구입니다. 담관암의 경우 아직 초기 단계이지만, 임상시험에서 면역 체크포인트 억제제 및 기타 면역 치료제가 환자의 예후를 개선할 수 있는 가능성을 검토하고 있습니다. 또한, 과학자들은 덜 침습적이고 더 정확한 진단 검사로 이어질 수 있는 혈액 및 담즙 내 바이오마커를 찾고 있으며, PET/CT 스캔 및 강화된 MRI 기술과 같은 영상 기술의 발전은 더 빠르고 정확한 진단에 기여하고 있습니다. 또한, 혈액 내 암세포와 DNA 조각을 검출하는 액체 생검의 역할은 질병의 진행과 치료에 대한 반응을 실시간으로 모니터링하는 데 있어 획기적인 역할을 할 수 있어 연구가 진행되고 있습니다.

담관암 치료 시장의 성장을 가속하는 요인은 무엇인가?

담관암 치료 시장의 성장은 혁신적인 치료 및 진단에 대한 수요 증가를 반영하는 몇 가지 요인에 의해 주도되고 있습니다. 주요 촉진요인 중 하나는 유전체 연구의 발전으로 특정 약물을 표적으로 삼을 수 있는 실용적인 유전자 돌연변이를 식별할 수 있게 되었습니다. 이는 표적치료제 개발의 새로운 길을 열어 특정 유전자 프로파일을 가진 환자들에게 보다 효과적인 치료 옵션을 제공할 수 있게 되었습니다. 또한, 담관암의 유병률이 증가하고 있으며, 특히 간흡충 감염과 같은 위험 요인으로 인해 발병률이 높은 지역에서는 더 나은 치료 옵션에 대한 수요가 증가하고 있습니다. 또 다른 중요한 요인은 의료진과 환자들 사이에서 이 질병에 대한 인식이 높아지면서 조기 진단과 조기 개입에 대한 중요성이 커지고 있다는 점입니다. 차세대 염기서열 분석 및 영상 진단 기술의 향상과 같은 첨단 진단 기술의 가용성이 높아짐에 따라 보다 정확하고 조기 발견이 가능해지면서 시장 성장에 기여하고 있습니다. 또한, 임상시험의 확대와 새로운 치료법 개발에 대한 제약사의 참여도 새로운 치료법의 도입을 가속화하고 있습니다. 이러한 요인들이 복합적으로 작용하여 담관암 치료 시장은 큰 성장을 이룰 것으로 예상되며, 향후 환자들의 예후가 개선될 것으로 기대됩니다.

조사 대상 기업 예시(총 56건)

  • AbbVie Inc.
  • Accord Healthcare, Inc.
  • Bayer AG
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • CONMED Corporation
  • Delcath Systems Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Intercept Pharmaceuticals, Inc.
  • Kyowa Kirin Co.
  • Merck & Co.
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals USA, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 24.10.04

Global Bile Duct Cancer Market to Reach US$382.6 Million by 2030

The global market for Bile Duct Cancer estimated at US$258.2 Million in the year 2023, is expected to reach US$382.6 Million by 2030, growing at a CAGR of 5.8% over the analysis period 2023-2030. Surgical Therapy, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$154.1 Million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 5.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$70.3 Million While China is Forecast to Grow at 9.6% CAGR

The Bile Duct Cancer market in the U.S. is estimated at US$70.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$82.5 Million by the year 2030 trailing a CAGR of 9.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Bile Duct Cancer Market - Key Trends and Drivers Summarized

What Makes Bile Duct Cancer So Complex and Challenging?

Bile duct cancer, also known as cholangiocarcinoma, is a rare but highly aggressive form of cancer that originates in the bile ducts, the thin tubes responsible for carrying bile from the liver to the gallbladder and small intestine. But what makes this cancer so particularly challenging? The complexity lies in its insidious nature; bile duct cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed to an advanced stage. By the time symptoms such as jaundice, abdominal pain, or unexplained weight loss appear, the disease is often already at a stage where treatment options are limited. Furthermore, the bile ducts' anatomical location, nestled deep within the liver and surrounded by vital organs, complicates both the diagnosis and surgical intervention. Imaging tests such as MRI, CT scans, and specialized techniques like cholangiography are essential for locating tumors, but they can be inconclusive or challenging to interpret due to the complex structure of the biliary system. This complexity underscores the urgent need for more effective diagnostic tools and early detection strategies in the fight against bile duct cancer.

Why Are Treatment Options for Bile Duct Cancer Limited?

Despite advancements in cancer treatment, why are options for bile duct cancer still so limited? The primary reason is the rarity of the disease, which has led to a lack of extensive research and clinical trials compared to more common cancers. The standard treatment for localized bile duct cancer is surgery, specifically resection of the affected portion of the bile duct or liver. However, surgery is only viable if the cancer is detected early and has not spread to other organs. Unfortunately, due to late diagnosis, many patients are not eligible for surgery, leaving chemotherapy and radiation as the mainstays of treatment. These therapies, while sometimes effective in slowing the progression of the disease, are not curative and often come with significant side effects. In recent years, there has been some progress in the development of targeted therapies and immunotherapy, which aim to attack cancer cells more precisely while sparing healthy tissue. Drugs targeting specific genetic mutations associated with bile duct cancer, such as FGFR2 and IDH1 inhibitors, have shown promise in clinical trials, offering hope for more effective treatments in the future. However, the heterogeneity of the cancer, with its various subtypes and molecular profiles, complicates the development of a one-size-fits-all treatment approach.

What Are the Latest Trends in Bile Duct Cancer Research?

Research into bile duct cancer is intensifying, but what are the latest trends that could change the outlook for patients? One significant trend is the growing focus on personalized medicine. Researchers are increasingly recognizing the importance of genetic profiling in understanding the unique characteristics of each patient’s cancer. By identifying specific genetic mutations and molecular targets, personalized treatment plans can be developed that are more effective than traditional chemotherapy. Another trend is the exploration of immunotherapy, which leverages the body’s immune system to fight cancer. Although still in its early stages for bile duct cancer, clinical trials are investigating the potential of immune checkpoint inhibitors and other immunotherapeutic agents to improve patient outcomes. Additionally, there is a push toward improving early detection methods, with scientists exploring biomarkers in blood and bile that could lead to less invasive and more accurate diagnostic tests. Advancements in imaging technologies, such as PET/CT scans and enhanced MRI techniques, are also contributing to earlier and more precise diagnoses. Moreover, the role of liquid biopsy, which detects cancerous cells or DNA fragments in the blood, is being studied as a potential game-changer in monitoring disease progression and response to treatment in real-time.

What Factors Are Driving the Growth in the Bile Duct Cancer Treatment Market?

The growth in the bile duct cancer treatment market is driven by several factors, reflecting the increasing demand for innovative therapies and diagnostics. One of the primary drivers is the advancement in genomic research, which has led to the identification of actionable genetic mutations that can be targeted with specific drugs. This has opened up new avenues for the development of targeted therapies, providing more effective treatment options for patients with specific genetic profiles. Additionally, the rising prevalence of bile duct cancer, particularly in regions with higher incidences due to risk factors like liver fluke infections, is fueling the demand for better treatment options. Another significant factor is the growing awareness of the disease among healthcare providers and patients, leading to earlier diagnosis and a greater emphasis on early-stage intervention. The increasing availability of advanced diagnostic technologies, such as next-generation sequencing and improved imaging techniques, is also contributing to the market's growth by enabling more accurate and earlier detection of the disease. Furthermore, the expansion of clinical trials and the involvement of pharmaceutical companies in the development of new treatments are accelerating the introduction of novel therapies. As these factors converge, the bile duct cancer treatment market is poised for significant growth, offering hope for improved patient outcomes in the future.

Select Competitors (Total 56 Featured) -

  • AbbVie Inc.
  • Accord Healthcare, Inc.
  • Bayer AG
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • CONMED Corporation
  • Delcath Systems Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Intercept Pharmaceuticals, Inc.
  • Kyowa Kirin Co. Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals USA, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Bile Duct Cancer - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Bile Duct Cancer Spurs Demand for Advanced Diagnostic Tools
    • Focus on Personalized Medicine Expands Addressable Market Opportunity for Targeted Therapies
    • Advancements in Genomic Research Propel Growth in Precision Oncology Solutions
    • Increasing Awareness of Rare Cancers Strengthens Business Case for Specialized Treatment Options
    • Development of Biomarker-Based Therapies Generates Demand for Companion Diagnostics
    • Innovations in Imaging Technology Drive Adoption of Early Detection Methods
    • Expansion of Clinical Trials for Bile Duct Cancer Accelerates Access to Experimental Treatments
    • Rising Healthcare Expenditure Creates New Opportunities for Advanced Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bile Duct Cancer Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bile Duct Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bile Duct Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bile Duct Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Surgical Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Intrahepatic Bile Duct Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Intrahepatic Bile Duct Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Intrahepatic Bile Duct Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Extrahepatic Bile Duct Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Extrahepatic Bile Duct Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Extrahepatic Bile Duct Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • JAPAN
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • CHINA
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • EUROPE
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Bile Duct Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Bile Duct Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Bile Duct Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • FRANCE
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • GERMANY
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Bile Duct Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Bile Duct Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Bile Duct Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • INDIA
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: India 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Bile Duct Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Bile Duct Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Bile Duct Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Bile Duct Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Bile Duct Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Bile Duct Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030
  • AFRICA
    • Bile Duct Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Bile Duct Cancer by Therapy - Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Bile Duct Cancer by Therapy - Percentage Breakdown of Value Sales for Surgical Therapy, Chemotherapy, Radiation Therapy, Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Bile Duct Cancer by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Bile Duct Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Bile Duct Cancer by Cancer Type - Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Bile Duct Cancer by Cancer Type - Percentage Breakdown of Value Sales for Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제